遏制血流:贝伐珠单抗对脑室下区胶质母细胞瘤患者生存的获益影响
该回顾性研究纳入2011年1月至2021年12月间诊治的67例新诊断脑室下区胶质母细胞瘤成人患者,比较首次复发后接受贝伐珠单抗治疗(45例)与未接受该治疗(22例)的生存差异。贝伐珠单抗作为二线治疗未影响总生存期,但显著延长首次复发后生存时间平均超过4个月,校正再手术后HR=0.57(95%CI 0.34-0.94,p=0.028),校正诊断至首次复发时间后亦与总生存期延长相关(HR=0.58,p=0.043)。作者认为贝伐珠单抗可能对复发后生存产生积极影响,需进一步研究确定最受益人群。
要点
- 贝伐珠单抗作为二线治疗未显著影响脑室下区胶质母细胞瘤患者的总生存期。
- 贝伐珠单抗显著延长首次复发后生存时间平均超过4个月,校正再手术后HR=0.57(95%CI 0.34-0.94,p=0.028)。
- 同时接受再手术和贝伐珠单抗的患者平均总生存期最长(22.16±7.81个月 vs 13.60±6.86个月,p=0.049),但HR=0.361(95%CI 0.108-1.209,p=0.085)未达统计学显著。
核心结论
- 贝伐珠单抗作为二线治疗可能对脑室下区胶质母细胞瘤患者复发后生存产生积极影响,即使作为单药治疗。
- 在某些尚未确定的亚人群中,贝伐珠单抗可能延长总生存期。
- 需要进一步研究以准确识别最可能从抗血管生成治疗中获益的脑室下区胶质母细胞瘤患者。
研究设计与样本
- 回顾性分析2011年1月至2021年12月间诊治的新诊断脑室下区胶质母细胞瘤成人患者的电子病历。
- 共纳入67例患者,其中45例(67.1%)在首次复发后接受贝伐珠单抗治疗,22例(32.9%)未接受。
- 比较两组患者的临床、手术、影像学和结局参数。
主要发现
- 两组间唯一具有统计学显著差异的指标是再手术率,非贝伐珠单抗组更高(40.9% vs 15.6%,p=0.023)。
- 贝伐珠单抗作为二线治疗总体上未影响脑室下区胶质母细胞瘤病例的总生存期。
- 贝伐珠单抗显著延长首次复发后生存时间平均超过4个月,校正再手术后HR=0.57(95%CI 0.34-0.94,p=0.028),校正再手术后HR=0.57(95%CI 0.34-0.97,PV=0.038)。
- 校正诊断至首次复发时间后,贝伐珠单抗治疗亦与总生存期延长相关(HR=0.58,p=0.043)。
- 亚组分析中,同时接受再手术和贝伐珠单抗的患者平均总生存期最长(22.16±7.81个月 vs 13.60±6.86个月,p=0.049;HR=0.361,95%CI 0.108-1.209,p=0.085)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Angiogenesis is a crucial step in tumorigenesis of glioblastoma (GBM). Bevacizumab, an anti-vascular endothelial growth factor drug, is approved for second-line therapy for GBM. Glioma stem cells, presumably the cell of origin of GBM, take an active role in angiogenesis. The subventricular zone (SVZ) is the brain's largest reservoir of neural stem cells, and GBM near this region (SVZ GBM) is associated with a poor prognosis. This study aims to evaluate the potential impact of second-line bevacizumab treatment on survival in patients with SVZ GBM. METHODS: The electronic medical records of adult patients with newly diagnosed SVZ GDM under treated between 1/2011 and 12/2021 were retrospectively reviewed. Clinical, surgical, radiological, and outcome parameters were compared between patients treated with bevacizumab after first relapse to patients without such treatment. RESULTS: The cohort included 67 patients. 45 (67.1%) were treated with bevacizumab after the first relapse while 22 (32.9%) were not. The only statistically significant difference between groups was the rate of re-surgery, which was higher in the non-bevacizumab group (40.9% vs. 15.6%; p = 0.023), indicating that the groups were quite homogenous. In general, bevacizumab as a second-line treatment did not affect OS in SVZ GBM cases. However, it significantly prolongs survival time from 1st relapse by an average of more than 4 months, including after adjustment to re-surgery variable (HR = 0.57, 95% CI 0.34-0.94, p = 0.028 and HR = 0.57, 95%CI = 0.34-0.97, PV = 0.038; respectively). Furthermore, when adjusting to time from diagnosis to 1st relapse, bevacizumab treatment was also associated with prolonged OS (HR = 0.58; p = 0.043). In a subgroup analysis, comparing patients treated with both re-surgery and bevacizumab to patients treated in any other way, patients with the combined treatment had the longest mean OS of the entire cohort (22.16 ± 7.81 m vs. 13.60 ± 6.86, p = 0.049; HR = 0.361 95%CI 0.108-1.209, p = 0.085). CONCLUSIONS: The use of bevacizumab as a second-line therapy in SVZ GBM cases may positively affect survival after relapse, even when given as a monotherapy. Additionally, in certain yet-to-be-identified sub-populations, bevacizumab may even extend overall survival. Further research is required to accurately identify SVZ GBM patients who would benefit most from anti-angiogenic therapy.
引用
- Laviv Y, Regev O, Kanner AA, et al. Stem the blood flow: beneficial impact of bevacizumab on survival of subventricular zone glioblastoma patients. J Neurooncol. 2024. PMID: 39316315. doi:10.1007/s11060-024-04828-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。